Korelacija između kvantifikacionih skorova metaboličkog sindroma i brojnih laboratorijskih parametara udruženih sa njim

  • Branko Srećković Clinical Center “Bežanijska kosa”, Belgrade, Serbia
  • Igor Mrdović Clinical Centre of Serbia, Clinic for Emergency Internal Medicine, Belgrade, Serbia
  • Ivan Soldatović University of Belgrade, Institute for Medical Statistics and Informatics, Belgrade, Serbia
  • Mirko Resan Miltary Medical Academy, Clinic for Ophthalmology, Belgrade, Serbia
  • Nenad Janeski Clinical Centre Zemun, Belgrade, Serbia
  • Emina Čolak Clinical Centre of Serbia, Institute of Medical Biochemistry, Belgrade, Serbia
  • Hristina Janeski University Children's Hospital, Belgrade, Serbia
  • Mirjana Šumarac-Dumanović University of Belgrade, Faculty of Medicine, Belgrade, Serbia
  • Miloš Joković University of Belgrade, Faculty of Medicine, Belgrade, Serbia
  • Nebojša Ivanović Clinical Center “Bežanijska kosa”, Belgrade, Serbia
  • Jasna Gačić Clinical Center “Bežanijska kosa”, Belgrade, Serbia
  • Vesna Dimitrijević-Srećković University of Belgrade, Faculty of Medicine, Belgrade, Serbia
DOI: https://doi.org/10.2298/VSP180626132S
Ključne reči: biomarkeri, homocistein, metabolički sindrom, rizik, procena, faktori rizika

Sažetak


Uvod/Cilj. Metabolički sindrom (MS) karakterišu osnovni faktori rizika [obim struka (OS), poremećaji glikoregulacije, hipertenzija, hipertrigliceridemija, nizak HDL-holesterol] kao i pridruženi faktori rizika – insulinska rezistencija (IR), C-reaktivni protein (CRP), mokraćna kiselina, inhibitor aktivacije plazminogena-1 (PAI-1), fibrinogen, hiperhomocisteinemija (HHci), nealkoholna masna bolest jetre (NAMBJ) i mikroalbuminurija. Cilj rada bio je da se analiziraju osnovni i pridruženi faktori rizika od MS kod bolesnika sa i bez MS i ustanovi korelacija siMS skora i siMS skora rizika sa osnovnim i pridruženim faktorima rizika od MS. Metode. Studijom su bila obuhvaćena 148 bolesnika sa prekomernom telesnom težinom [body mass index ((BMI) 25–30 kg/m2) i gojazni (BMI > 30 kg/m2), starosti 30–75 godina, podeljeni u dve grupe: I – sa MS (68 bolesnika) i II – bez MS (80 bolesnika). Korišćeni su siMS skor, kao metod za kvantifikaciju MS, i siMS skor rizika, kao indikator aterosklerotskih komplikacija. Rezultati. Bolesnici sa MS imali su statistički značajno više vrednosti OS, hipertenzije, triglicerida (p < 0,001), glikemije (p = 0,006), kao i pridruženih faktora rizika od MS [HOMA IR (p = 0,002) CRP (p = 0,01) mokraćne kiseline (p < 0,001), alanin aminotranferaze (ALT) (p = 0,007) i gama-glutamil transferaze (GGT) (p = 0,001)] i niže vrednosti HDL-holesterol, (p < 0,001) u odnosu na bolesnika bez MS. Skor siMS pokazao je korelaciju sa pridruženim faktorima MS [log HOMA IR, logCRP, mokraćnom kiselinom (p < 0,001) i fibrinogenom (p = 0,005), parametrima jetrene funkcije: logALT (p = 0,001), log GGT, (p < 0,001) i bubrežne funkcije: kreatininom (p = 0,013) i serumskim proteinima (p = 0,006)]. Skor siMS rizika je statistički značajno korelirao sa vrednostima homocisteina, trombocita, mokraćne kiseline, uree, albumina i proteina. Zaključak. Statistički značajno više vrednosti pridruženih faktora rizika od MS (HOMA-R, CRP, mokraćne kiseline, ALT, GGT) kod bolesnika sa MS potvrđene su i korelacijom sa siMS skorom. Skor siMS ukazuje na to da su insulinska rezisencija, CRP, fibrinogen, mokraćna kiselina, NAMBJ pridruženi faktori rizika od MS. Skor siMS rizika ukazuje na to da gojaznost i hiperproteinski unos povećavaju HHCi sa starenjem, te da povećavaju rizik od bubrežnih poremećaja i aterosklerotskih komplikacija.

Reference

Kumar A, Palfrey HA, Pathak R, Kadowitz PJ, Gettys TW, Murthy SN. The metabolism and significance of homocysteine in nu-trition and health. Nutr Metab (Lond) 2017; 14: 78.

Catena C, Colussi G, Nait F, Capobianco F, Sechi LA. Elevated Homocysteine Levels Are Associated With the Metabolic Syndrome and Cardiovascular Events in Hypertensive Pa-tients. Am J Hypertens 2015; 28(7): 943–50.

Fonseca V, Dicker-Brown A, Ranganathan S, Sing W, Barnard RJ, Fink L, et al. Effects of high-fat-sucrose diet on enzymes in homocysteine metabolism in the rat. Metabolism 2000; 49(6): 736–41.

Oron-Herman M, Rosenthal T, Sela BA. Hyperhomocysteinemia as a component of syndrome X. Metabolism 2003; 52(11): 1491–5.

Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, et al. Metabolic szndrome and risk incident cardiovascu-lar events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007; 49(4): 403–14.

Garcin JM, Cremades S, Garcia-Hejl C, Bordier L, Dupuy O, Ma-yaudon H, et al. Is hyperhomocysteinemia an additional risk factor of the metabolic syndrome? Metab Syndr Relat Disord 2006; 4(3): 185–95.

Srećković B, Soldatovic I, Colak E, Mrdovic I, Sumarac-Dumanovic M, Janeski H, et al. Homocysteine is the confounding factor of metabolic syndrome-confirmed by siMS score. Drug Metab Pers Ther 2018; 33(2): 99–103.

Soldatovic I, Vukovic R, Culafic D, Gajic M, Dimitrijevic-Sreckovic V. siMS Score: Simple Method for Quantifying Metabolic Syndrome. PLoS One 2016; 11(1): e0146143.

de Carvalho SC, Muniz MT, Siqueira MD, Siqueira ER, Gomes AV, Silva KA, et al. Plasmatic higher levels of homocysteine in non-alcoholic fatty liver disease (NAFLD). Nutr J 2013; 12: 37.

Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyper-homocysteinemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997, 95: 1119–21.

Papatheodorou L, Weiss N. Vascular oxidant stress and inflam-mation in hyperhomocysteinemia. Antioxid Redox Signal 2007; 9(11): 1941–58.

Sreckovic B, Sreckovic VD, Soldatovic I, Colak E, Sumarac-Dumanovic M, Janeski H, et al.. Homocysteine is a marker for metabolic syndrome and atherosclerosis. Diabetes Metab Syndr 2017; 11(3): 179–82.

Abd El-Kader SM, El-Den Ashmawy EM. Non-alcoholic fatty liver disease: The diagnosis and management. World J Hepatol 2015; 7(6): 846–58.

McCully KS. Vascular pathology of homocysteinemia: implica-tions for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56(1): 111–28.

Faeh D, Chiolero A, Paccaud F. Homocysteine as a risk factor for cardiovascular disease: should we (still) worry about? Swiss Med Wkly 2006; 136(47–48): 745–56.

Li Y, Jiang C, Xu G, Wang N, Zhu Y, Tang C, et al. Homocys-teine upregulates resistin production from adipocytes in vivo and in vitro. Diabetes 2008; 57(4): 817–27.

Sheu WH, Lee WJ, Chen YT. Plasma homocysteine concentra-tions and insulin sensitivity in hypertensive subjects. Am J Hypertens 2000; 13(1Pt 1): 14–20.

Srećković B. Determination of homocysteine level as an inde-pendent risk factor for coronary heart disease [subspeciality thesis]. Belgrade: Faculty of Medicine, University of Belgrade; 2010. (Serbian)

Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to defini-tion. Circulation 2004; 109(3): 433–8.

Gowdaiah PK, Mamatha TR, Nirgude D, Hosamani PB. High sen-sitivity C-reactive protein in metabolic syndrome. Int J Adv Med 2016; 3(3): 607–10.

Mauras N, Delgiorno C, Kollman C, Bird K, Morgan M, Sweeten S, et al. Obesity without established comorbidities of the meta-bolic syndrome is associated with a proinflammatory and pro-thrombotic state, even before the onset of puberty in children. J Clin Endocrinol Metab 2010; 95(3): 1060–8.

Dimitrijević Srećković V. Metabolic syndrome, prediabetes and non alcoholic fatty liver diseases- treatment by Mediterranean diet. In: Dimitrijević Srećković V, Vukašinović V, editors. FAST-ING-A WAY TO LIFE- Christian fasting as a method for preventing and treating diabetes, atherosclerosis and cancer. Vrnjci: Interklima-grafika; 2013. p. 37–49.

Čolak E, Pap D, Majkić Singh-N, Obradović I. The Association of obesity and liver enzyme activities in a student population at Increased Risk for Cardiovascular Disease. J Med Biochem 2013; 32(1): 26–31.

Ciba I, Widhalm K. The Association between the non-alcoholic fatty liver disease and insulin resistance in obese children and 20 adolescents. Acta Pediatr 2007; 96: 109–12.

Garcia-Tevijano ER, Berasain C, Rodriguez JA, Corrales FJ, Arias R, Martin-Duce A, et al. Hyperhomocysteinemia in liver cirrho-sis: mechanisms and role in vascular and hepatic fibrosis. Hy-pertension 2001; 38(5): 1217–21.

Pacana T, Cazanave S, Verdianelli A, Patel V, Min HK, Mirshahi F, et al. Dysregulated Hepatic Methionine Metabolism Drives Homocysteine Elevation in Diet-Induced Nonalcoholic Fatty Liver Disease. PLoS One 2015; 10(8): e0136822.

Dimitrijević-Srećković V. Metabolic sindrome in children and adolescents. In: Nedeljković S, editor. Yugoslav study of athero-sclerosis precursors in school children, 20 years of follow-up. Belgrade: Faculty of Medicine, University of Belgrade; 2011. p. 731–45. (Serbian)

Berstad P, Konstantinova SV, Refsum H, Nurk E, Vollset SE, Tell GS, et al. Dietary fat and plasma total homocysteine concen-trations in 2 adult age groups: the Hordaland Homocysteine Study. Am J Clin Nutr 2007; 85(6): 1598–605.

Jager A, Kostense PJ, Nijpels G, Dekker JM, Heine RJ, Bouter LM, et al. Serum homocysteine levels are associated with the development of (micro)albuminuria: the Hoorn study. Arteri-oscler Thromb Vasc Biol 2001; 21(1): 74–81.

Dimitrijević-Srećković V. Mediterranean cardioprotective nutri-tion. In: Nedeljković S, editor. Yugoslav study of atherosclerosis precursors in school children, 20 years of follow-up. Belgrade: Faculty of Medicine, University of Belgrade; 2011. p.

Han L, Liu Y, Wang C, Tang L, Feng X, Astell-Burt T, et al. Determinants of hyperhomocysteinemia in healthy and hyper-tensive subjects: A population-based study and systematic re-view. Clin Nutr 2017; 36(5): 1215–30.

Objavljeno
2021/04/08
Broj časopisa
Vol. 77 Br. 8 (2020): Vojnosanit pregl
Rubrika
Originalni članak